glp-1 drugs for obesity Agonists: Using Semaglutide, Tirzepatide, and Orforglipron Weight Loss and GLP-1 Therapy for Obesity Requires

All of these factors contribute to sustainable weight loss over time

doi: 10.1093/jnci/92.18.1472 206 BruntonSAWyshamCH

These direct-to-consumer programs offered by the manufacturers have dramatically reduced cash costs for people without insurance

How can payers, life sciences companies, and other healthcare stakeholders keep pace with demand for GLP-1s

4.8 Electrolytes (Potassium, Sodium) Physiological Role Electrolytes regulate: Fluid balance Cardiac conduction Neuromuscular function Why GLP-1 Therapy May Influence Electrolytes Electrolyte imbalance may occur secondary to: Persistent vomiting Diarrhoea Reduced fluid intake Rapid weight loss This is most relevant during dose escalation or in patients with ongoing GI symptoms

List Prices and Savings Programs Novo Nordisk, the manufacturer of semaglutide, offers several savings programs to make the medication more affordable for eligible patients